Patents by Inventor John Tyhonas

John Tyhonas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF RAF KINASES
    Publication number: 20260055084
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: April 18, 2025
    Publication date: February 26, 2026
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, John TYHONAS, Eric MURPHY
  • INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
    Publication number: 20250333399
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: April 29, 2025
    Publication date: October 30, 2025
    Inventors: Stephen W. Kaldor, John Tyhonas, Eric A. Murphy, Toufike Kanouni, Lee D. Arnold, Robert Kania, Jason M. Cox
  • Inhibitors of fibroblast growth factor receptor kinases
    Patent number: 12331039
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: June 17, 2025
    Assignee: Khora SPV 1, LLC
    Inventors: Stephen W. Kaldor, John Tyhonas, Eric A. Murphy, Toufike Kanouni, Lee D. Arnold, Robert Kania, Jason M. Cox
  • Inhibitors of RAF kinases
    Patent number: 12312336
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: May 27, 2025
    Assignee: PIERRE FABRE MÉDICAMENT
    Inventors: Stephen W. Kaldor, Toufike Kanouni, John Tyhonas, Eric Murphy
  • INHIBITORS OF CDK4/6 KINASE
    Publication number: 20250163063
    Abstract: Provided herein are inhibitors of CDK4/6 kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said CDK4/6 kinase inhibitory compounds for the treatment of disease.
    Type: Application
    Filed: January 25, 2023
    Publication date: May 22, 2025
    Inventors: John TYHONAS, Toufike KANOUNI, Jason M. COX, Robert S. KANIA, Xiaohu S. OUYANG
  • SOLID STATE FORMS OF AN FGFR INHIBITOR
    Publication number: 20250059170
    Abstract: The present disclosure relates to solid state forms of 1-((3S,5R)-1-acryloyl-5-(methoxymethyl)pyrrolidin-3-yl)-3-((1-cyclopropyl-4, 6-difluoro-1H-benzo[d]imidazol-5-yl)ethynyl)-5-(methylamino)-1H-pyrazole-4-carboxamide. Such solid state forms are useful in preparation of pharmaceutical compositions and dosage forms for the treatment of disease.
    Type: Application
    Filed: December 7, 2022
    Publication date: February 20, 2025
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, Andrew PHIMISTER, Jayachandra P. REDDY, John TYHONAS, Shubham CHOPADE, Preetanshu PANDEY, Jason M. COX, Robert KANIA
  • TREATMENT OF CANCER WITH AN FGFR KINASE INHIBITOR
    Publication number: 20250032458
    Abstract: Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise an FGFR kinase inhibitor. Some embodiments comprise combination therapy featuring the FGFR kinase inhibitor with at least one oncology therapeutic agent.
    Type: Application
    Filed: December 7, 2022
    Publication date: January 30, 2025
    Inventors: Aleksandra FRANOVIC, Angie VASSAR, Nichol MILLER, Ken KOBAYASHI, Richard Thomas WILLIAMS, John TYHONAS, Robert KANIA, Jason M. COX, Neolito TIMPLE, Eric S. MARTIN, Eric A. MURPHY
  • INHIBITORS OF RAF KINASES
    Publication number: 20240182467
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: September 29, 2023
    Publication date: June 6, 2024
    Inventors: Toufike KANOUNI, Jason M. COX, John TYHONAS, Robert S. KANIA, Subhas J. CHAKRAVORTY, Young K. CHEN
  • INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
    Publication number: 20230374015
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: June 4, 2021
    Publication date: November 23, 2023
    Inventors: Stephen W. KALDOR, John TYHONAS, Eric A. MURPHY, Toufike KANOUNI, Lee D. ARNOLD, Robert KANIA
  • Inhibtors of Raf kinases
    Patent number: 11814384
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: November 14, 2023
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Jason M. Cox, John Tyhonas, Robert S. Kania, Subhas J. Chakravorty, Young K. Chen
  • INHIBITORS OF RAF KINASES
    Publication number: 20230303566
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: February 3, 2023
    Publication date: September 28, 2023
    Inventors: Toufike KANOUNI, Jason M. COX, John TYHONAS, Robert S. KANIA, Subhas J. CHAKRAVORTY, Young K. CHEN
  • INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
    Publication number: 20230174535
    Abstract: Provided herein are inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: May 14, 2020
    Publication date: June 8, 2023
    Inventors: Stephen W. KALDOR, John TYHONAS
  • INHIBITORS OF RAF KINASES
    Publication number: 20230081390
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: March 20, 2020
    Publication date: March 16, 2023
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, Eric A. MURPHY, Lee D. ARNOLD, John TYHONAS
  • INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
    Publication number: 20230078839
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: March 23, 2022
    Publication date: March 16, 2023
    Inventors: Stephen W. KALDOR, John TYHONAS, Eric A. MURPHY, Toufike KANOUNI, Lee D. ARNOLD, Robert KANIA, Jason M. COX
  • TREATMENT OF CANCER WITH CDK12/13 INHIBITORS
    Publication number: 20230074545
    Abstract: Provided herein are compositions and methods for the treatment of a triple-negative breast cancer, ovarian cancer and castration-resistant prostate cancer. Said compositions comprise CDK12/13 inhibitors.
    Type: Application
    Filed: December 23, 2020
    Publication date: March 9, 2023
    Inventors: Eric A. MURPHY, John TYHONAS, Noelito TIMPLE, Toufike KANOUNI, Lee D. ARNOLD, Elisabeth GARDINER, Eric MARTIN
  • INHIBITORS OF CYCLIN-DEPENDENT KINASES
    Publication number: 20220388990
    Abstract: Provided herein are compounds which are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: July 16, 2020
    Publication date: December 8, 2022
    Inventors: Toufike KANOUNI, Lee D. ARNOLD, Stephen W. KALDOR, Eric A. MURPHY, John TYHONAS
  • INHIBITORS OF RAF KINASES
    Publication number: 20220340543
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: April 26, 2022
    Publication date: October 27, 2022
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, John TYHONAS, Eric MURPHY, Jason COX, Robert KANIA
  • Inhibitors of RAF kinases
    Patent number: 11407737
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: September 16, 2021
    Date of Patent: August 9, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, John Tyhonas, Eric Murphy, Jason Cox, Robert Kania
  • Inhibitors of cyclin-dependent kinases
    Patent number: 11390618
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: July 19, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
  • Inhibitors of cyclin-dependent kinases
    Patent number: 11358958
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: June 14, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas